Physiogenex will be presenting its innovative obese NASH hamster model at the 20th World Congress of Insulin resistance, Los Angeles, CA, USA, Dec.1-3, 2022. The abstract entitled “Empagliflozin improves heart failure with preserved ejection fraction despite limited effects on NASH in non-diabetic and diabetic diet-induced obese hamsters” will be presented as a poster during each session break by Dr. François Briand, our Director of Research and Business Development.
Unlike mouse and rat, the obese NASH hamster has a human-like lipoprotein/bile acids profile, shows evident hepatocellular ballooning and portal/bridging (stage 2-3) fibrosis, and develops heart failure with preserved ejection fraction (HFpEF).
Reach out to François Briand during the meeting to learn how Physiogenex animal models and CRO services will drive your preclinical development of drugs targeting metabolic diseases to success.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.